Amivantamab, a bispecific EGFR/MET antibody, has emerged as a promising therapy for NSCLC, particularly in patients with EGFR mutations such as exon 20 insertions and those with progression following osimertinib therapy. The gene discussed is MET; the disease is non-small cell lung carcinoma.